Amgen (AMGN) Return on Capital Employed (2009 - 2026)
Amgen (AMGN) posted quarterly Return on Capital Employed of 15.87% for Q1 2026, up 486.0% year-over-year from 2.71% in Q1 2025, and up 13.39% quarter-over-quarter from 14.0% in Q4 2025.
Amgen (AMGN) Return on Capital Employed (2009 - 2026) Analysis & Trends
Amgen's Return on Capital Employed history runs 17 years deep, the most recent figure standing at 15.87% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 486.0% year-over-year to 15.87%; the TTM figure through Mar 2026 stood at 15.87% (up 486.0% YoY), while the FY2025 annual figure was 13.82%, up 365.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 15.87%, up from 14.0% in the prior quarter.
- The five-year high for Return on Capital Employed was 20.44% in Q3 2022, with the low at 8.79% in Q2 2024.
- The 5-year median for Return on Capital Employed is 12.9% (2025), against an average of 13.55%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed soared 499 bps in 2022, then plunged 917 bps in 2023.
- Amgen's Return on Capital Employed stood at 19.63% in 2022, then slumped by 47 bps to 10.47% in 2023, then grew by 2 bps to 10.63% in 2024, then surged by 32 bps to 14.0% in 2025, then climbed by 13 bps to 15.87% in 2026.
- Business Quant data shows AMGN's Return on Capital Employed at 15.87% in Q1 2026, 14.0% in Q4 2025, and 12.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.66% |
| Mar 31, 2026 | 15.87% |
| Dec 31, 2025 | 14.00% |
| Sep 30, 2025 | 12.90% |
| Jun 30, 2025 | 12.02% |
| Mar 31, 2025 | 11.01% |
| Dec 31, 2024 | 10.63% |
| Sep 30, 2024 | 8.81% |
| Jun 30, 2024 | 8.79% |
| Mar 31, 2024 | 9.25% |
| Dec 31, 2023 | 10.47% |
| Sep 30, 2023 | 12.06% |
| Jun 30, 2023 | 13.12% |
| Mar 31, 2023 | 14.33% |
| Dec 31, 2022 | 19.63% |
| Sep 30, 2022 | 20.44% |
| Jun 30, 2022 | 20.07% |
| Mar 31, 2022 | 16.94% |
| Dec 31, 2021 | 15.01% |
| Sep 30, 2021 | 15.45% |